Submitted:
05 March 2024
Posted:
05 March 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Material and Methods
2.1. Study Population
2.2. Evaluation of Indicators
2.3. Follow-Up
2.4. Statistical Analyses
3. Results
4. Discussion
5. Study limitations
6. Conclusions
Funding
Conflict of Interest
References
- Sattartabar, B.; Ajam, A.; Pashang, M.; Jalali, A.; Sadeghian, S.; Mortazavi, H.; Mansourian, S.; Bagheri, J.; Karimi, A.A.; Hosseini, K. Sex and age difference in risk factor distribution, trend, and long-term outcome of patients undergoing isolated coronary artery bypass graft surgery. BMC Cardiovasc. Disord. 2021, 21, 460. [Google Scholar] [CrossRef] [PubMed]
- Ayati, A.; Akbari, K.; Shafiee, A.; Zoroufian, A.; Jalali, A.; Samimi, S.; Pashang, M.; Hosseini, K.; Bagheri, J.; Masoudkabir, F. Time-varying effect of postoperative cholesterol profile on long-term outcomes of isolated coronary artery bypass graft surgery. Lipids Health Dis. 2023, 22, 163. [Google Scholar] [CrossRef] [PubMed]
- Yuan, S.; Li, F.; Zhang, H.; Zeng, J.; Su, X.; Qu, J.; Lin, S.; Gu, D.; Rao, C.; Zhao, Y.; Zheng, Z. Impact of High Lipoprotein(a) on Long-Term Survival Following Coronary Artery Bypass Grafting. J Am Heart Assoc. 2024, e031322. [Google Scholar] [CrossRef]
- Neumann, F.J.; Sousa-Uva, M.; Ahlsson, A.; Alfonso, F.; Banning, A.P.; Benedetto, U.; Byrne, R.A.; Collet, J.P.; Falk, V.; Head, S.J.; et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019, 40, 87–165. [Google Scholar] [CrossRef]
- Bauer, T.M.; Yaser, J.M.; Daramola, T.; Mansour, A.I.; Ailawadi, G.; Pagani, F.D.; Theurer, P.; Likosky, D.S.; Keteyian, S.J.; Thompson, M.P. Cardiac Rehabilitation Reduces 2-Year Mortality After Coronary Artery Bypass Grafting. Ann. Thorac. Surg. 2023, 116, 1099–1105. [Google Scholar] [CrossRef]
- Townsend, R.R.; Wilkinson, I.B.; Schiffrin, E.L., et al.; et al. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American Heart Association. Hypertension 2015, 66, 698–722. [Google Scholar] [CrossRef] [PubMed]
- Shirai, K.; Utino, J.; Otsuka, K.; Takata, M. A novel blood pressure-independent arterial wall stiffness parameter: Cardio-ankle vascular index (CAVI). J. Atheroscler. Thromb. 2006, 13, 101–107. [Google Scholar] [CrossRef]
- Shirai, K.; Hiruta, N.; Song, M.; Kurosu, T.; Suzuki, J.; Tomaru, T.; Miyashita, Y.; Saiki, A.; Takahashi, M.; Suzuki, K.; et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: Theory, evidence and perspectives. J. Atheroscler. Thromb. 2011, 18, 924–938. [Google Scholar] [CrossRef]
- Matsushita, K.; Ding, N.; Kim, E.D.; Budoff, M.; Chirinos, J.A.; Fernhall, B.; Hamburg, N.M.; Kario, K.; Miyoshi, T.; Tanaka, H.; Townsend, R. Cardio-ankle vascular index and cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies. J. Clin. Hypertens (Greenwich) 2019, 21, 16–24. [Google Scholar] [CrossRef]
- Nagayama, D. Psychological stress-induced increase in the cardio-ankle vascular index (CAVI) may be a predictor of cardiovascular events. Hypertens Res. 2022, 45, 1672–1674. [Google Scholar] [CrossRef] [PubMed]
- Gohbara, M.; Iwahashi, N.; Sano, Y.; Akiyama, E.; Maejima, N.; Tsukahara, K.; Hibi, K.; Kosuge, M.; Ebina, T.; Umemura, S.; Kimura, K. Clinical Impact of the Cardio-Ankle Vascular Index for Predicting Cardiovascular Events After Acute Coronary Syndrome. Circ. J. 2016, 80, 1420–1426. [Google Scholar] [CrossRef]
- Kirigaya, J.; Iwahashi, N.; Tahakashi, H.; Minamimoto, Y.; Gohbara, M.; Abe, T.; Akiyama, E.; Okada, K.; Matsuzawa, Y.; Maejima, N.; Hibi, K.; Kosuge, M.; Ebina, T.; Tamura, K.; Kimura, K. Impact of Cardio-Ankle Vascular Index on Long-Term Outcome in Patients with Acute Coronary Syndrome. J. Atheroscler. Thromb. 2020, 27, 657–668. [Google Scholar] [CrossRef]
- Otsuka, T.; Fukuda, S.; Shimada, K., et al.; et al. Serial assessment of arterial stiffness by cardio-ankle vascular index for prediction of future cardiovascular events in patients with coronary artery disease. Hypertens Res. 2014, 37, 1014–1020. [Google Scholar] [CrossRef] [PubMed]
- Sumin, A.N.; Shcheglova, A.V.; ZHidkova, I.I., et al.; et al. Assessment of arterial stiffness by cardio-ankle vascular index for prediction of five-year cardiovascular events after coronary artery bypass surgery. Glob Heart. 2021, 16, 90. [Google Scholar] [CrossRef]
- Shirai, K.; Saiki, A.; Nagayama, D.; Tatsuno, I.; Shimizu, K.; Takahashi, M. The Role of Monitoring Arterial Stiffness with Cardio-Ankle Vascular Index in the Control of Lifestyle-Related Diseases. Pulse 2015, 3, 118–133. [Google Scholar] [CrossRef]
- Peng, F.; Pan, H.; Wang, B.; Lin, J.; Niu, W. The impact of angiotensin receptor blockers on arterial stiffness: A meta-analysis. Hypertens Res. 2015, 38, 613–620. [Google Scholar] [CrossRef]
- Saiki, A.; Watanabe, Y.; Yamaguchi, T.; Ohira, M.; Nagayama, D.; Sato, N.; Kanayama, M.; Takahashi, M.; Shimizu, K.; Moroi, M.; Miyashita, Y.; Shirai, K.; Tatsuno, I. CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. J. Atheroscler. Thromb. 2021, 28, 1083–1094. [Google Scholar] [CrossRef] [PubMed]
- Sumin, A.N.; Shcheglova, A.V.; Ivanov, S.V.; Barbarash, O.L. Long-Term Prognosis after Coronary Artery Bypass Grafting: The Impact of Arterial Stiffness and Multifocal Atherosclerosis. J. Clin. Med. 2022, 11, 4585. [Google Scholar] [CrossRef]
- Shimizu, K.; Takahashi, M.; Shirai, K. A huge earthquake hardened arterial stiffness monitored with cardio-ankle vascular index. J. Atheroscler. Thromb. 2013, 20, 503–511. [Google Scholar] [CrossRef] [PubMed]
- Tajima, T.; Ikeda, A.; Steptoe, A.; Takahashi, K.; Maruyama, K.; Tomooka, K.; Saito, I.; Tanigawa, T. The independent association between salivary alpha-amylase activity and arterial stiffness in Japanese men and women: The Toon Health Study. Hypertens Res. 2022, 45, 1249–1262. [Google Scholar] [CrossRef]
- Kume, D.; Nishiwaki, M.; Hotta, N.; Endoh, H. Impact of acute mental stress on segmental arterial stiffness. Eur. J. Appl. Physiol. 2020, 120, 2247–2257. [Google Scholar] [CrossRef] [PubMed]
- Shimizu, K.; Takahashi, M.; Sato, S.; Saiki, A.; Nagayama, D.; Harada, M.; Miyazaki, C.; Takahara, A.; Shirai, K. Rapid Rise of Cardio-Ankle Vascular Index May Be a Trigger of Cerebro-Cardiovascular Events: Proposal of Smooth Muscle Cell Contraction Theory for Plaque Rupture. Vasc Health Risk Manag. 2021, 17, 37–47. [Google Scholar] [CrossRef]
- Shimizu, K.; Takahashi, M.; Sato, S.; Saiki, A.; Nagayama, D.; Hitsumoto, T.; Takahara, A.; Shirai, K. Rapid Rise in Cardio-Ankle Vascular Index as a Predictor of Impending Cardiovascular Events -Smooth Muscle Cell Contraction Hypothesis for Plaque Rupture. Vasc Health Risk Manag. 2022, 18, 879–886. [Google Scholar] [CrossRef]
- Uemura, K.; Yamada, M.; Kuzuya, M.; Okamoto, H. Effects of Active Learning Education on Arterial Stiffness of Older Adults with Low Health Literacy: A Randomized Controlled Trial. J. Atheroscler. Thromb. 2021, 28, 865–872. [Google Scholar] [CrossRef]
- Zhou, Z.; Hou, L.; Cui, M.; Mourot, L.; Zhu, W. Acute effects of low-volume intermittent versus higher-volume continuous exercise on arterial stiffness in healthy young men. Sci. Rep. 2022, 12, 1749. [Google Scholar] [CrossRef]
- Kawabata, T.; Kubozono, T.; Ojima, S.; Kawasoe, S.; Akasaki, Y.; Salim, A.A.; Ikeda, Y.; Miyata, M.; Takenaka, T.; Ohishi, M. Insufficient blood pressure control is independently associated with increased arterial stiffness. Hypertens Res. 2022, 45, 1861–1868. [Google Scholar] [CrossRef] [PubMed]
- Nagayama, D.; Fujishiro, K.; Suzuki, K.; Shirai, K. Comparison of Predictive Ability of Arterial Stiffness Parameters Including Cardio-Ankle Vascular Index, Pulse Wave Velocity and Cardio-Ankle Vascular Index0. Vasc Health Risk Manag. 2022, 18, 735–745. [Google Scholar] [CrossRef]
- Kario, K.; Kabutoya, T.; Fujiwara, T.; Negishi, K.; Nishizawa, M.; Yamamoto, M.; Yamagiwa, K.; Kawashima, A.; Yoshida, T.; Nakazato, J.; Matsui, Y.; Sekizuka, H.; Abe, H.; Abe, Y.; Fujita, Y.; Sato, K.; Narita, K.; Tsuchiya, N.; Kubota, Y.; Hashizume, T.; Hoshide, S. Rationale, design, and baseline characteristics of the Cardiovascular Prognostic COUPLING Study in Japan (the COUPLING Registry). J. Clin. Hypertens (Greenwich). 2020, 22, 465–474. [Google Scholar] [CrossRef] [PubMed]




| Group with improved CAVI (n=94) | Group with impaired CAVI (n=116) | P-value | |
| Age, years | 57.5 [53.0; 64.0] | 59.0 [55.0; 64.5] | 0.118 |
| Male, n (%) | 66 (70.2) | 87 (75.0) | 0.437 |
| Height, cm | 169.0 [163.0; 176.0] | 170.0 [164.0; 176.0] | 0.646 |
| Weight, kg | 80.0 [72.0; 90.0] | 80.0 [70.0; 89.0] | 0.914 |
| Body mass index, kgm–2 | 28.1 [24.6; 31.6] | 28.0 [25.5; 31.1] | 0.861 |
| Myocardial infarction, (n %) | 54 (57.5) | 72 (62.1) | 0.496 |
| Hypertension, n (%) | 73 (77.7) | 104 (89.7) | 0.017 |
| Stroke, (n %) | 6 (6.4) | 9 (7.8) | 0.7 |
| Transischemic attack, (n %) | 0 | 2 (1.72) | 0.2 |
| Diabetes, n (%) | 7 (7.5) | 23 (19.8) | 0.011 |
| PCI, (n %) | 4 (4.3) | 9 (7.8) | 0.294 |
| CABG, (n %) | 1 (1.1) | 1 (0.9) | 0.881 |
| Carotid endarterectomy, (n %) | 0 | 3 (2.6) | 0.116 |
| Smoking experience, years | 30.0 [20.0; 40.0] | 30.0 [20.0; 40.0] | 0.478 |
| Smoking, (n %) | 20 (21.3) | 32 (27.6) | 0.292 |
| Group with improved CAVI (n=94) |
Group with impaired CAVI (n=116) |
P-value | |
| The clinical characteristics | |||
| Angina basal (n %) | 73 (77.7) | 94 (81.0) | 0.546 |
| Angina after year (n %) | 9 (9.6) | 10 (8.6) | 0.812 |
| Heart failure II-III FK NYHA basal (n, %) | 18 (19.2) | 41 (35.3) | 0.009 |
| Heart failure II-III FK NYHA after year (n, %) | 12 (12.9) | 15 (13.2) | 0.956 |
| Laboratory data | |||
| Total cholesterol basal, mmol/L | 5.0 [4.2; 5.9] | 4.6 [4.0; 5.6] | 0.056 |
| Total cholesterol after year, mmol/L | 4.9 [4.1; 6.2] | 4.35 [3.7; 5.5] | 0.019 |
| LDL cholesterol basal, mmol/L | 3.04 [2.1; 3.9] | 2.8 [2.22; 3.5] | 0.139 |
| LDL cholesterol after year, mmol/L | 3.2 [2.3; 3.8] | 2.4 [1.9; 3.4] | 0.017 |
| Fasting glucose basal, mmol/L basal | 5.5 [5.0; 6.2] | 5.6 [5.2; ] | 0.155 |
| Fasting glucose after year, mmol/L | 5.5 [5.0; 6.2] | 5.8 [5.3; 6.9] | 0.066 |
| GFR CKD-EPI basal, ml/min/1.73 m2 | 80.9 [65.5; 102.7] | 82.1 [65.4; 97.7] | 0.966 |
| GFR CKD-EPI after year, ml/min/1.73m2 | 92.8 [70.6; 112.7] | 86.2 [71.4;106.0] | 0.553 |
| Echocardiography | |||
| LV ejection fraction basal, % | 60.0 [54.0; 64.0] | 60.0 [53.0; 64.0] | 0.483 |
| LV ejection fraction after year, % | 62.0 [57.0; 65.0] | 61.0 [51.0; 65.0] | 0.116 |
| E/A basal | 0.88 [0.7; 1.2] | 0.8 [0.7; 1.1] | 0.653 |
| E/A after year | 0.8 [0.51; 1.1] | 0.68 [0.5; 1.0] | 0.133 |
| Vasera-1000 | |||
| R-CAVI basal | 8.4 [7.6; 9.3] | 8.5 [7.9; 9.3] | 0.458 |
| R-CAVI after year | 7.7 [7.1; 8.2] | 9.1 [8.6; 9.7] | <0.001 |
| L-CAVI basal | 7.6 [7.1; 8.1] | 8.5 [7.9; 9.4] | 0.371 |
| L-CAVI after year | 7.7 [7.1; 8.1] | 9.1 [8.3; 9.6] | <0.001 |
| R- ABI basal | 1.12 [1.03; 1.22] | 1.14 [1.08; 1.2] | 0.351 |
| R- ABI after year | 1.08 [099; 1.17] | 1.09 [0.99; 1.19] | 0.501 |
| L- ABI basal | 1.1 [1.02; 1.16] | 1.11 [1.04; 1.18] | 0.402 |
| L-ABI after year | 1.03 [0.92; 1.11] | 1.05 [094; 1.13] | 0.117 |
| Group with improved CAVI (n=94) |
Group with impaired CAVI (n=116) |
P-value | |
| Coronary angiography | |||
| LCA ≥50%, (n %) | 17 (18.1) | 29 (25.0) | 0.228 |
| Single-vessel coronary artery ≥70%, (n %) | 17 (18.1) | 26 (22.41) | 0.429 |
| Bicavascular coronary artery ≥70%, (n, %) | 30 (31.9) | 38 (32.8) | 0.896 |
| Tricovascular coronary artery (n, %) | 40 (42.6) | 46 (39.7) | 0.671 |
| Non-coronary atherosclerosis | |||
| Carotid artery stenosis ≥30%, basal (n,%) | 17 (18.1) | 21 (18.1) | 0.997 |
| Carotid artery stenosis≥30%, after year (n,%) | 22 (24.4) | 27 (23.7) | 0.899 |
| Carotid artery stenosis ≥50%, basal (n,%) | 11 (11.7) | 16 (13.8) | 0.652 |
| Carotid artery stenosis ≥50%, after year (n,%) | 7 (7.8) | 12 (10.5) | 0.502 |
| Group with improved CAVI (n=94) | Group with impaired CAVI (n=116) |
P-value | |
| Euroscore (scores) | 2.5 [1.0; 4.0] | 2.0 [2.0; 4.0] | 0.630 |
| Euroscore, % | 1.33 (0.88; 2.35) | 1.54 (1.0; 2.4) | 0.464 |
| Cardiopulmonary bypass, (n %) | 84 (89.4) | 96 (82.8) | 0.174 |
| Number of shunts | 3.0 [2.0; 3.0] | 3.0 [2.0; 3.0] | 0.542 |
| Cardiopulmonary bypass time, minutes | 98.5 [77.5; 110.0] |
94.0 [84.0; 107.0] |
0.795 |
| Total operation time, minutes | 240.0 [204.0; 300.0] | 240.0 [195.0; 273.0] | 0.330 |
| Ventriculoplasty, (n %) | 5 (5.32) | 4 (3.5) | 0.505 |
| Thrombectomy, (n, %) | 4 (4.3) | 1 (0.9) | 0.108 |
| Carotid endarterectomy, (n %) | 1 (1.1) | 3 (2.6) | 0.422 |
| Radiofrequency ablation, (n %) | 1 (1.1) | 3 (2.6) | 0.422 |
| Group with improved CAVI (n=94) | Group with impaired CAVI (n=116) |
P-value | |
| Preoperative medicine therapy | |||
| Beta-blockers, n (%) | 62 (66.0) | 74 (63.8) | 0.943 |
| CCBs, n (%) | 20 (21.3) | 25 (21.6) | 0.883 |
| Statins, n (%) | 44 (46.8) | 62 (54.9) | 0.248 |
| ARB, n (%) | 7 (7.5) | 10 (8.6) | 0.714 |
| ACEI, n (%) | 44 (46.8) | 54 (46.6) | 0.982 |
| Aspirin, n (%) | 62 (66.0) | 82 (70.7) | 0.303 |
| 1 years medicine therapy | |||
| Beta-blockers, n (%) | 76 (80.8) | 98 (84.5) | 0.543 |
| CCBs, n (%) | 26 (27.7) | 25 (21.6) | 0.283 |
| Statins, n (%) | 84 (89.4) | 107 (92.2) | 0.623 |
| ARB, n (%) | 62 (65.6) | 76 (65.5) | 0.861 |
| ACEI, n (%) | 7 (7.5) | 11 (9.5) | 0.616 |
| Aspirin, n (%) | 80 (85.1) | 102 (87.9) | 0.682 |
| 10 years medicine therapy | |||
| Beta-blockers, n (%) | 57 (60.6) | 65 (56.0) | 0.501 |
| CCBs, n (%) | 23 (24.5) | 22 (19.0) | 0.333 |
| Statins, n (%) | 62 (65.9) | 69 (59.5) | 0.335 |
| ARB, n (%) | 41 (43.6) | 51 (44.0) | 0.959 |
| ACEI, n (%) | 19 (20.2) | 14 (12.1) | 0.106 |
| Aspirin, n (%) | 60 (63.8) | 65 (56.0) | 0.252 |
| B | S.E. | Wald | df | Sig. | Exp(B) | ||
| All-cause mortality | |||||||
| Step 1 | Number of shunts | 0.551 | 0.213 | 6.704 | 1 | 0.010 | 1.735 |
| Constant | -2.646 | 0.593 | 19.912 | 1 | 0.000 | 0.071 | |
| Step 2 | Group with impaired CAVI | 0.876 | 0.376 | 5.421 | 1 | 0.020 | 2.400 |
| Number of shunts | 0.609 | 0.221 | 7.580 | 1 | 0.006 | 1.839 | |
| Constant | -4.185 | 0.929 | 20.306 | 1 | 0.000 | 0.015 | |
| Step 3 | Group with impaired CAVI | 0.852 | 0.378 | 5.083 | 1 | 0.024 | 2.345 |
| Carotid stenoses ≥30% | 0.843 | 0.432 | 3.810 | 1 | 0.051 | 2.323 | |
| Number of shunts | 0.627 | 0.226 | 7.685 | 1 | 0.006 | 1.873 | |
| Constant | -4.367 | 0.942 | 21.518 | 1 | 0.000 | 0.013 | |
| Combined end-point (all-cause death + non-fatal myocardial infarction + non-fatal stroke) | |||||||
| Step 1 | Carotid stenoses ≥30% | 1.186 | 0.389 | 9.293 | 1 | 0.002 | 3.274 |
| Constant | -0.829 | 0.173 | 22.982 | 1 | 0.000 | 0.436 | |
| Step 2 | Group with impaired CAVI | 0.853 | 0.322 | 6.995 | 1 | 0.008 | 2.346 |
| Carotid stenoses ≥30% | 1.208 | 0.398 | 9.201 | 1 | 0.002 | 3.347 | |
| Constant | -2.166 | 0.549 | 15.595 | 1 | 0.000 | 0.115 | |
| Test Result Variable(s) | Asymptotic 95% Confidence Interval | ||||
| Area | Std. Error | Asymptotic Sig. | Lower Bound | Upper Bound | |
| R_CAVI basal | 0.541 | 0.043 | 0.326 | 0.457 | 0.626 |
| L_CAVI basal | 0.530 | 0.043 | 0.481 | 0.446 | 0.613 |
| R_CAVI after year | 0.550 | 0.042 | 0.235 | 0.467 | 0.633 |
| L_CAVI_after year | 0.532 | 0.041 | 0.448 | 0.452 | 0.612 |
| Group with impaired CAVI | 0.596 | 0.041 | 0.023 | 0.516 | 0.676 |
| Carotid stenoses ≥30% | 0.577 | 0.043 | 0.068 | 0.493 | 0.661 |
| Test Result Variable(s) | Asymptotic 95% Confidence Interval | ||||
| Area | Std. Error | Asymptotic Sig. | Lower Bound | Upper Bound | |
| R_CAVI basal | 0.541 | 0.049 | 0.397 | 0.444 | 0.637 |
| L_CAVI basal | 0.514 | 0.049 | 0.767 | 0.419 | 0.610 |
| R_CAVI after year | 0.567 | 0.048 | 0.165 | 0.472 | 0.662 |
| L_CAVI_after year | 0.547 | 0.047 | 0.330 | 0.455 | 0.639 |
| Group with impaired CAVI | 0.590 | 0.046 | 0.062 | 0.499 | 0.681 |
| Carotid stenoses ≥30% | 0.554 | 0.050 | 0.266 | 0.456 | 0.651 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).